Eachan Johnson commited on
Commit
6e70e00
·
1 Parent(s): a33e613

Add figures

Browse files
README.md CHANGED
@@ -18,14 +18,14 @@ Access the notebook explaining the models [here](https://github.com/scbirlab/202
18
 
19
  **Figure 1.** The rate of antibacterial drug discovery has reached a plateau, while the rate of emergence of new resistance is constant.
20
 
21
- <img src="nb-outputs/year-vs-ttr.png" alt="" width="300">
22
 
23
  **(A)** The time between discovery and resistance detection compared to the discovery year for classes of antibacterial drugs. Colour indicates the time between discovery and clinical use. Outliers in time to resistance (labelled with a canonical example in parentheses) are characterised by a longer gap between discovery and clinical use.
24
 
25
- <img src="nb-outputs/ttr-hist.png" alt="" width="300">
26
 
27
  **(B)** The distribution of time between discovery and resistance for classes of antibacterial drugs follows an exponential distribution (Poisson maximum likelihood fit shown by blue line), with a half-life of ~15 years (95% confidence interval: 10–20 years).
28
 
29
- <img src="nb-outputs/resistance-curves.png" alt="" width="300">
30
 
31
  **(C)** Poisson maximum likelihood best fits for the dynamics of antibacterial drug discovery. The number of classes with resistance not-yet-detected (light blue line) as a function of time was modelled as the difference between the number of discovered classes, $D$ (orange line), and the number of classes with detected resistance, $R$ (dark blue line). $R$ was modelled as exponential growth with rate $t_{1/2}$. $D$ was modelled as the coupon collector problem when sampling from $k$ antibacterial drug classes at a constant rate $n$ after a ~28 year lag phase, $t_{\text{lag}}$. Data were obtained from [Stennett, Back, and Race](https://doi.org/10.3390/antibiotics11091237).
 
18
 
19
  **Figure 1.** The rate of antibacterial drug discovery has reached a plateau, while the rate of emergence of new resistance is constant.
20
 
21
+ <img src="figs/year-vs-ttr.png" alt="" width="300">
22
 
23
  **(A)** The time between discovery and resistance detection compared to the discovery year for classes of antibacterial drugs. Colour indicates the time between discovery and clinical use. Outliers in time to resistance (labelled with a canonical example in parentheses) are characterised by a longer gap between discovery and clinical use.
24
 
25
+ <img src="figs/ttr-hist.png" alt="" width="300">
26
 
27
  **(B)** The distribution of time between discovery and resistance for classes of antibacterial drugs follows an exponential distribution (Poisson maximum likelihood fit shown by blue line), with a half-life of ~15 years (95% confidence interval: 10–20 years).
28
 
29
+ <img src="figs/resistance-curves.png" alt="" width="300">
30
 
31
  **(C)** Poisson maximum likelihood best fits for the dynamics of antibacterial drug discovery. The number of classes with resistance not-yet-detected (light blue line) as a function of time was modelled as the difference between the number of discovered classes, $D$ (orange line), and the number of classes with detected resistance, $R$ (dark blue line). $R$ was modelled as exponential growth with rate $t_{1/2}$. $D$ was modelled as the coupon collector problem when sampling from $k$ antibacterial drug classes at a constant rate $n$ after a ~28 year lag phase, $t_{\text{lag}}$. Data were obtained from [Stennett, Back, and Race](https://doi.org/10.3390/antibiotics11091237).
figs/resistance-curves.png ADDED
figs/ttr-hist.png ADDED
figs/year-vs-ttr.png ADDED